U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H25NO6
Molecular Weight 399.437
Optical Activity ( - )
Additional Stereochemistry Yes
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0
Stereo Comments M-helix

SHOW SMILES / InChI
Structure of Colchicine

SMILES

COC1=CC2=C(C(OC)=C1OC)C3=CC=C(OC)C(=O)C=C3[C@H](CC2)NC(C)=O

InChI

InChIKey=IAKHMKGGTNLKSZ-INIZCTEOSA-N
InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H25NO6
Molecular Weight 399.437
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Colchicine is an alkaloid obtained from the plant colchicum autumnale (also known as "meadow saffron"). Colchicine is an alternative medication for those unable to tolerate NSAIDs in gout. Mechanism of action of colchicine is inhibition of microtubule polymerization by binding to tubulin. Availability of tubulin is essential to mitosis, so colchicine effectively unctions as a "mitotic poison" or spindle poison.

CNS Activity

Curator's Comment: Known to be CNS non-penetrant in rats. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
COLCRYS

Approved Use

Colchicine capsules are indicated for prophylaxis of gout flares in adults. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby preventing the activation, degranulation, and migration of neutrophils to sites of inflammation.

Launch Date

2009
Primary
COLCRYS

Approved Use

Colchicine is indicated for Familial Mediterranean fever (FMF) in adults and children 4 years or older

Launch Date

2009
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.68 ng/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
2.16 ng/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2023.29 pg/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: oral
experiment type: single
co-administered:
COLCHICINE plasma
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18.47 ng × h/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
19.9 ng × h/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
8717.33 pg*h/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: oral
experiment type: single
co-administered:
COLCHICINE plasma
Homo sapiens
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
30.54 h
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
31.04 h
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
61%
COLCHICINE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unknown, 42 years
n = 1
Health Status: unknown
Age Group: 42 years
Sex: M
Population Size: 1
Sources:
Other AEs: Myelosuppression...
Other AEs:
Myelosuppression (grade 4, 1 patient)
Sources:
3 mg 1 times / day multiple, oral
MTD
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (27%)
Vomiting (13%)
Diarrhea (20%)
Injection site reactions (20%)
Myalgia (27%)
Arthralgia (7%)
Allergic reaction (7%)
Sources:
12 mg single, oral
Overdose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
unknown, 56 years
n = 1
Health Status: unknown
Age Group: 56 years
Sex: M
Population Size: 1
Sources:
Other AEs: Rhabdomyolysis...
Other AEs:
Rhabdomyolysis (grade 5, 1 patient)
Sources:
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Acute pancreatitis, Epigastric pain...
AEs leading to
discontinuation/dose reduction:
Acute pancreatitis (1 patient)
Epigastric pain (severe, 1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Sources:
0.6 mg 2 times / day multiple, oral
Dose: 0.6 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.6 mg, 2 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: Thoracic Surgery
Population Size: 49
Sources:
Other AEs: Acute respiratory distress syndrome, Fall...
Other AEs:
Acute respiratory distress syndrome (serious, 3 patients)
Fall (serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Myelosuppression grade 4, 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unknown, 42 years
n = 1
Health Status: unknown
Age Group: 42 years
Sex: M
Population Size: 1
Sources:
Vomiting 13%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Diarrhea 20%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Injection site reactions 20%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Myalgia 27%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Nausea 27%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Allergic reaction 7%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Arthralgia 7%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Rhabdomyolysis grade 5, 1 patient
12 mg single, oral
Overdose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
unknown, 56 years
n = 1
Health Status: unknown
Age Group: 56 years
Sex: M
Population Size: 1
Sources:
Acute pancreatitis 1 patient
Disc. AE
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Nausea 1 patient
Disc. AE
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Vomiting 1 patient
Disc. AE
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Epigastric pain severe, 1 patient
Disc. AE
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Fall serious, 2 patients
0.6 mg 2 times / day multiple, oral
Dose: 0.6 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.6 mg, 2 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: Thoracic Surgery
Population Size: 49
Sources:
Acute respiratory distress syndrome serious, 3 patients
0.6 mg 2 times / day multiple, oral
Dose: 0.6 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.6 mg, 2 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: Thoracic Surgery
Population Size: 49
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
yes
likely (co-administration study)
Comment: Although there are no published case reports for colchicine toxicity when co-administered with the 4 inhibitors that the sponsor employed, i.e., voriconazole, fluconazole, cimetidine and propafenone, several published case reports indicate that colchicine toxicity is observed when it is co-administered with drugs that are potent inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin, ketoconazole) as well as potent P-gp inhibitors (e.g., cyclosporine).
Page: 2.0
yes
yes (co-administration study)
Comment: Co-administration with posaconazole (considered a strong CYP3A4 inhibitor) increased AUC of colchcine by approximately 3-fold; Although there are no published case reports for colchicine toxicity when co-administered with the 4 inhibitors that the sponsor employed, i.e., voriconazole, fluconazole, cimetidine and propafenone, several published case reports indicate that colchicine toxicity is observed when it is co-administered with drugs that are potent inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin, ketoconazole) and strong to moderate inhibitors of CYP3A4 (e.g., grapefruit juice, erythromycin).
Page: 2.0
PubMed

PubMed

TitleDatePubMed
Colchicine-induced lesions in the rat duodenum.
1975
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
1991 Jan-Feb
Colchicine myopathy in a case of familial Mediterranean fever: immunohistochemical and ultrastructural study of accumulated tubulin-immunoreactive material.
1992
Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4.
1992 Apr
[Toxic myopathy with kidney failure as a colchicine side effect ifn familial Mediterranean fever].
1992 Aug 14
Colchicine myoneuropathy and renal dysfunction.
1992 Dec
Rapid-onset colchicine myoneuropathy.
1992 Dec
Colchicine-induced myoneuropathy in a renal transplant patient.
1992 Jun
Acute neuromyopathy after colchicine treatment.
1992 Nov
[Treatment of AL-amyloidosis and some other types of amyloidosis].
2001 Jan
Anti-inflammatory fibrosis suppression in threatened trabeculectomy bleb failure produces good long term control of intraocular pressure without risk of sight threatening complications.
2002 Dec
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
2002 Sep-Oct
Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles.
2003 Aug
Colchicine myopathy in a patient with familial Mediterranean fever and normal renal function.
2003 Aug 15
Colchicine-induced rhabdomyolysis in a patient with chronic heart failure.
2003 Dec
Colchicine-induced myopathy in a teenager with familial Mediterranean fever.
2003 Dec
[A case of Behçet's disease associated with neuromyopathy induced by combination therapy with colchicine and cyclosporin].
2003 Feb
Colchicine induces apoptosis in organotypic hippocampal slice cultures.
2003 Feb 28
Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site.
2003 Jun 6
The role of the cytoskeleton in mechanotransduction in human osteoblast-like cells.
2003 May
Exocytotic "constipation" is a mechanism of tubulin/lysosomal interaction in colchicine myopathy.
2003 May 1
Differential effects of stretch and compression on membrane currents and [Na+]c in ventricular myocytes.
2003 May-Jul
Case report. Hepatic portal venous gas: transient radiographic finding associated with colchicine toxicity.
2003 Nov
Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis.
2003 Oct
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 33-2003. A 37-year-old man with a history of alcohol and drug abuse and sudden onset of leg weakness.
2003 Oct 23
Colchicine-induced myopathy with myotonia in a patient with chronic renal failure.
2003 Sep
Lithium prevents colchicine-induced apoptosis in rat cerebellar granule neurons.
2004 Apr
Microtubule disarray in primary cultures of human hepatocytes inhibits transcriptional activity of the glucocorticoid receptor via activation of c-jun N-terminal kinase.
2004 Dec
Colchicine myotoxicity: case reports and literature review.
2004 Dec
RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance.
2004 Dec 20
Severe respiratory muscle weakness related to long-term colchicine therapy.
2004 Feb
Effects of colchicine on liver functions of cirrhotic rats: beneficial effects result from stellate cell inactivation and inhibition of TGF beta1 expression.
2004 Jan 15
[Abdominal pain and recurrent cholestatic jaundice].
2004 Jun 9
Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil.
2004 May
[Experimental study on Sorbaria sorbifolia extract against chronic liver damage in rats].
2004 Oct
Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.
2004 Oct 1
Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats.
2004 Sep
Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium.
2005
Monozygotic twins concordant for intestinal Behçet's disease.
2005 Apr
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
2005 Apr
Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.
2005 Aug 1
Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer.
2005 May
Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier.
2005 Sep 17
Colchicine myoneuropathy in chronic renal failure patients with gout.
2006 Apr
Involvement of cytoskeleton in AhR-dependent CYP1A1 expression.
2006 Apr
Preplaced cell division: a critical mechanism of autoprotection against S-1,2-dichlorovinyl-L-cysteine-induced acute renal failure and death in mice.
2006 Aug
Colchicine and HMG Co-A reductase inhibitors induced myopathy-a case report.
2006 Dec
A role for mixed lineage kinases in granule cell apoptosis induced by cytoskeletal disruption.
2006 Mar
Synthesis and biological evaluation of B-ring modified colchicine and isocolchicine analogs.
2006 May 15
Cyclosporine not the only agent to cause Guillain-Barré-like syndrome after solid-organ transplant.
2006 Nov
Patents

Sample Use Guides

In Vivo Use Guide
For prophylaxis of gout flares, the recommended dosage of Colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals.
Route of Administration: Oral
In Vitro Use Guide
Inhibition of the polymerization of brain tubulin was evaluated. Solution of compound in DMSO in serial dilutions was prepared. Reaction mixture contained 0.25 mg of tubulin, 1.0 M monosodium glutamate and approptiate drug concentrations. The reaction mixtures were incubated at 37 °C for 15 min to allow slow binding drugs like colchicine to bind to the tubulin. The reaction mixtures were then chilled on ice, and the polymerization reaction was followed turbidimetrically for 20 min. Polymer formation was confirmed by evaluation of depolymerization at 0°C. Extent of inhibition of polymerization at 20 min in drug-treated samples was always calculated by comparing them to a pair of drug-free samples in each experimental set.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:19:06 GMT 2023
Edited
by admin
on Fri Dec 15 17:19:06 GMT 2023
Record UNII
SML2Y3J35T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Colchicine
EP   HSDB   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USP  
Official Name English
NSC-757
Code English
COLCHICINUM
HPUS   WHO-IP LATIN  
Common Name English
ACETAMIDE, N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO(A)HEPTALEN-7-YL)-,(S)-
Common Name English
COLCHICINE COMPONENT OF PROBEN-C
Common Name English
COLCHICINE [WHO-IP]
Common Name English
(S)-N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO(A)HEPTALEN-7-YL)ACETAMIDE
Systematic Name English
COLCHICINE [USP MONOGRAPH]
Common Name English
COLBENEMID COMPONENT COLCHICINE
Common Name English
COLCHICINE COMPONENT OF COLBENEMID
Common Name English
COLCHICINE COMPONENT OF COL-PROBENECID
Common Name English
Colchicine [WHO-DD]
Common Name English
COLCHICINE [USP-RS]
Common Name English
COLCHICINE [EP IMPURITY]
Common Name English
COLCHCINE [VANDF]
Common Name English
LODOCO
Brand Name English
GLOPERBA
Brand Name English
(-)-COLCHICINE
Common Name English
MITIGARE COMPONENT COLCHICINE
Brand Name English
PROBEN-C COMPONENT COLCHICINE
Common Name English
COLCHICINUM [WHO-IP LATIN]
Common Name English
COLCRYS
Brand Name English
COLCHINEOS
Common Name English
COLCHICINE [ORANGE BOOK]
Common Name English
COLCHICINE COMPONENT OF MITIGARE
Brand Name English
COLCHICINE [MI]
Common Name English
COLCHICINUM [HPUS]
Common Name English
COLCHICINE [EP MONOGRAPH]
Common Name English
COLCHICINE [JAN]
Common Name English
COLCHICINE [MART.]
Common Name English
COL-PROBENECID COMPONENT COLCHICINE
Common Name English
COLCHISOL
Common Name English
COLCHICINE [HSDB]
Common Name English
Classification Tree Code System Code
WHO-VATC QM04AC01
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
FDA ORPHAN DRUG 11085
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
FDA ORPHAN DRUG 245707
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
FDA ORPHAN DRUG 245807
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
NCI_THESAURUS C67421
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
WHO-ATC M04AC01
Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023
LIVERTOX NBK548068
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
Code System Code Type Description
ECHA (EC/EINECS)
200-598-5
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
HSDB
3044
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
COLCHICINE
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY Description: Pale yellow to pale greenish yellow crystals, amorphous scales or a powder; odourless or almost odourless.Solubility: Soluble in water; freely soluble in ethanol (~750 g/l) TS; slightly soluble in ether R.Category: Antigout drug.Storage: Colchicine should be kept in a tightly closed container, protected from light.Additional information: Colchicine is an alkaloid obtained from Colchicum autumnale L. (Fam. Liliaceae). It darkens on exposureto light. CAUTION: Colchicine is extremely poisonous and must be handled with care.
LACTMED
Colchicine
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
MERCK INDEX
m3725
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY Merck Index
FDA UNII
SML2Y3J35T
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
MESH
D003078
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
ChEMBL
CHEMBL107
Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023
PRIMARY
PUBCHEM
6167
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
NDF-RT
N0000000239
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY P-Glycoprotein Interactions [MoA]
NDF-RT
N0000182141
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
DAILYMED
SML2Y3J35T
Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023
PRIMARY
CAS
64-86-8
Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023
PRIMARY
NCI_THESAURUS
C385
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
CHEBI
27882
Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023
PRIMARY
EPA CompTox
DTXSID5024845
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
DRUG CENTRAL
726
Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023
PRIMARY
IUPHAR
2367
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
NSC
757
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
RS_ITEM_NUM
1146006
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
RXCUI
2683
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
COLCHICINE
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
EVMPD
SUB01420MIG
Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023
PRIMARY
SMS_ID
100000090556
Created by admin on Fri Dec 15 17:19:07 GMT 2023 , Edited by admin on Fri Dec 15 17:19:07 GMT 2023
PRIMARY
DRUG BANK
DB01394
Created by admin on Fri Dec 15 17:19:06 GMT 2023 , Edited by admin on Fri Dec 15 17:19:06 GMT 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
TARGET->INHIBITOR OF AGGREGATION
DESTABILIZES TUBULIN POLYMERS
DERIVATIVE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
APICAL
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
URINE
METABOLITE LESS ACTIVE -> PARENT
URINE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC